Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05098340

Circulating circRNA in Acute Ischemic Stroke

CRAST is to analyze the expression pattern of circular RNA (circRNA) by bioinformatics analysis in patients with acute ischemic stroke and healthy control. The candidate circRNA will be verified as biomarkers for the detection and prognosis of acute ischemic stroke.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Circular RNAs have been highlighted to be involved in the pathological process of ischemic stroke (IS). The purpose of this protocol will investigate the expression pattern of circular RNA (circRNA) by bioinformatics analysis in patients with acute ischemic stroke and healthy control. The candidate circRNA will be verified as biomarkers for the detection and prognosis of acute ischemic stroke. Distinctive expression patterns of circRNA will be identified by individual quantitative real time polymerase chain reaction (qRT-PCR). A diagnostic or predictive model will be established using logistic regression. The panel of these altered circRNAs may be associated with acute IS and could serve as a novel diagnostic or predictive method.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18 years or older
  • Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan
  • Within 72 hours of symptom onset
  • Good performance status
  • Signed an approved informed consents

Exclusion criteria

  • a history of hemorrhagic infarction, chronic kidney/liver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases

Treatment and study plan

Quantitative Real-time polymerase chain reaction

Genetic

Quantitative Real-time polymerase chain reaction of circular RNA (circRNA).

Primary outcomes

  1. Differential expression pattern of circRNA

    Time frame: 90 days

    Differential expression pattern of circular RNA (circRNA) will be compared between AIS group and HC group, thus candidate circRNA will be verified as biomarkers for the detection and prognosis of AIS.

Secondary outcomes

  1. Dynamic changes of circRNA during the follow-up period

    Time frame: 90 days

    Dynamic changes of circRNA will be explored before and after endovascular therapy

  2. Correlation of circRNA and stroke-associated infection

    Time frame: 30 days

    Correlation of circRNA and stroke-associated infection will be explored in acute ischemic stroke.

  3. Correlation of circRNA and inflammatory factors in acute ischemic stroke

    Time frame: 7 days

    Correlation of circRNA and inflammatory factors on admission will be explored in acute ischemic stroke.

  4. Prognostic value of circRNA in acute ischemic stroke

    Time frame: 90 days

    The prognosis of AIS patients will be analyzed between differential expressed candidate circRNA after they have completed the systematic therapy.

Study contacts

Contact information is provided by the study sponsor or research team.

Xingzhi Wang, MD

CONTACT

[email protected]

0086-13852000759

Sponsors and collaborators

Lead sponsor

The Affiliated Hospital of Xuzhou Medical University

Other

Registry information

Official study title

Clinical Significance of Circulating circRNA in Acute Ischemic Stroke (CRAST)

Acronym: CRAST

Important dates

Study start
2020
Primary completion
2024
Study completion
2024
First posted
Oct 28, 2021
Registry last updated
Aug 6, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.